Article in ASN neuro. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 3 institutions in 2 countries.
Michael Ohene-NyakoPharmacology and Toxicology, School of Medicine, 6886Virginia Commonwealth University, Richmond, VA, USA.
Sara R NassPharmacology and Toxicology, School of Medicine, 6886Virginia Commonwealth University, Richmond, VA, USA.
Hope T RichardPathology, School of Medicine, 6886Virginia Commonwealth University, Richmond, VA, USA.
Robert LukandePathology, College of Health Sciences, 58589Makerere University, Kampala, Uganda.
Melanie R NicolExperimental and Clinical Pharmacology, College of Pharmacy, 15515University of Minnesota, Minneapolis, MN, USA.
MaryPeace McRaePharmacotherapy and Outcomes Science, School of Pharmacy, 15535Virginia Commonwealth University, Richmond, VA, USA.
Pamela E KnappPharmacology and Toxicology, School of Medicine, 6886Virginia Commonwealth University, Richmond, VA, USA.ORCID 0000-0003-4364-6074
Kurt F HauserPharmacology and Toxicology, School of Medicine, 6886Virginia Commonwealth University, Richmond, VA, USA.ORCID 0000-0001-7886-0332
Virginia Commonwealth University · USMakerere University · UGUniversity of Minnesota · US
Funding
The Manhattan HIV Brain BankU24MH100931 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MORGELLO, SUSAN · 2013 to 2023
$14.0M
Texas NeuroAIDS Research CenterU24MH100930 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GELMAN, BENJAMIN B. · 2013 to 2023
$12.1M
NNTC Data Coordinating CenterU24MH100925 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI FOX, HOWARD S, SHERMAN, SETH · 2013 to 2022
$9.5M
MOR and CCR5 interactive signaling mediates opiate and HIV-driven synaptodendritic injuryR01DA034231 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F, KNAPP, PAMELA E · 2013 to 2023
$5.4M
Innovative therapeutic approaches to address excitotoxic CNS/neuronal damage in opioid-neuroHIV comorbidityR01DA057346 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kurt F Hauser, Pamela E Knapp · 2022 to 2026
$3.4M
HIV opiate interactions in white matter pathologyR01DA044939 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F, KNAPP, PAMELA E · 2017 to 2021
$2.7M
Selective vulnerability of discrete neural circuits in the striatum to HIV-opiate comorbidityR01DA045588 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI HAUSER, KURT F · 2018 to 2022
$2.0M
HIV and opiate interactions in behavioral and anterior cingulate cortex synaptic dysfunctionF32DA053163 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NASS, SARA · 2021 to 2022
summary statementHIV/HIV-1 Tat and morphine independently increase pathologic phosphorylation of TAR DNA binding protein 43 in the striatum. HIV- and opioid-induced pathologic phosphorylation of TAR DNA binding protein 43 may involve enhanced CK2 activity and protein levels.
Indexed as
HIV-1HIV InfectionsAnalgesics, OpioidBasal GangliaCasein Kinase IIDNA-Binding ProteinsHumansPhosphorylationProtein Bindingtat Gene Products, Human Immunodeficiency VirusAnalgesics, OpioidCasein Kinase IIDNA-Binding Proteinstat Gene Products, Human Immunodeficiency Viruscasein kinase 2CX-4945 (Silmitasertib)inositol-triphosphate 3-kinase Bneuro-acquired human immunodeficiency syndrome (neuroHIV)opioid use disorderTDP-43 proteinopathy
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Casein Kinase 2 Mediates HIV- and Opioid-Induced Pathologic Phosphorylation of TAR DNA Binding Protein 43 in the Basal Ganglia. · full record | OpenQuestion